Irbesartan Clonmel (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal glands. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, leading to vessel relaxation, reduced sodium‑water retention, lower blood pressure, and decreased pressure within the kidney’s filtering units.

The appropriate dose of Irbesartan Clonmel is determined by the prescribing clinician based on the individual’s blood pressure, kidney function, and overall health status. Dosage adjustments are made according to therapeutic response and tolerability, following local prescribing guidelines.

Safety of Irbesartan in pregnancy has not been established, and it is generally avoided because of potential fetal toxicity. Limited data exist for breastfeeding; therefore, the drug should be used only if the potential benefit outweighs the risk, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers or diuretics, ARBs specifically target the renin‑angiotensin system, making them especially useful in patients with diabetic kidney disease.

Irbesartan Clonmel tablets should be stored at room temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Irbesartan Clonmel is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks include angioedema, which can cause swelling of the face, lips, tongue or throat, and hyperkalemia, a potentially life‑threatening rise in blood potassium. Acute renal impairment may also occur, especially when combined with other nephrotoxic agents. Prompt medical attention is required if any of these symptoms develop.

Irbesartan Clonmel is contraindicated in patients with known hypersensitivity to irbesartan or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment and in those taking dual renin‑angiotensin system blockers (e.g., ACE inhibitor plus ARB) unless specifically directed by a physician.